New way to combat Lyme disease performs will in mid-stage trial – The Pharma Letter

Californias Tarsus Pharmaceuticals (Nasdaq: TARS) has announced positive top-line results from the Phase IIa CARPO trial.

The Irvine-based company is running the trial to test the efficacy of TP-05, also known as lotilaner, in the prevention of Lyme disease.

The most common vector-borne disease in the USA, Lyme disease is transmitted to humans following the bite of ticks which carry it.

If caught early, a short course of oral antibiotics, such

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

See more here:

New way to combat Lyme disease performs will in mid-stage trial - The Pharma Letter